An introduction to PET-CT imaging
V Kapoor, BM McCook, FS Torok - Radiographics, 2004 - pubs.rsna.org
Cancer is one of the leading causes of morbidity and mortality in developed countries such
as the United States. Complex clinical decisions about treatment of oncologic patients are …
as the United States. Complex clinical decisions about treatment of oncologic patients are …
Combined PET-CT in the head and neck: part 1. Physiologic, altered physiologic, and artifactual FDG uptake
…, CH Snyderman, BF Branstetter IV, BM McCook… - Radiographics, 2005 - pubs.rsna.org
Positron emission tomography (PET) with 2-[fluorine-18] fluoro-2-deoxy-d-glucose (FDG)
has been effective for the diagnosis, staging, and restaging of malignancies of the head and …
has been effective for the diagnosis, staging, and restaging of malignancies of the head and …
18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer
…, B Degirmenci, JM Mountz, BM McCook… - Journal of Nuclear …, 2007 - Soc Nuclear Med
PET using 18 F-FDG has been shown to effectively detect various types of cancer by their
increased glucose metabolism. The aim of this study was to evaluate the use of coregistered …
increased glucose metabolism. The aim of this study was to evaluate the use of coregistered …
Prevalence effect in a laboratory environment
…, SK Golla, S Katyal, JM Lacomis, BM McCook… - Radiology, 2003 - pubs.rsna.org
PURPOSE: To measure observer performance at various levels of prevalence. MATERIALS
AND METHODS: A multiobserver multiabnormality receiver operating characteristic (ROC) …
AND METHODS: A multiobserver multiabnormality receiver operating characteristic (ROC) …
Role of 18FFDG PET/CT in the Treatment of Head and Neck Cancers: Posttherapy Evaluation and Pitfalls
…, MB Fukui, BM McCook - American Journal of …, 2005 - Am Roentgen Ray Soc
Kapoor V, Fukui MB, McCook BM n the United States, extracranial head and neck carcinomas
constitute 2–3% of cancers [1], whereas globally they represent 5.4% of all cancers (…
constitute 2–3% of cancers [1], whereas globally they represent 5.4% of all cancers (…
Diffuse bone marrow uptake on whole-body F-18 fluorodeoxyglucose positron emission tomography in a patient taking recombinant erythropoietin
…, JT Ames, FS Torok, BM McCook… - Clinical nuclear …, 2004 - journals.lww.com
F-18 fluorodeoxyglucose (FDG)–positron emission tomography (PET) is used extensively in
oncology to diagnose, stage, and restage patients with various malignancies. Many patients …
oncology to diagnose, stage, and restage patients with various malignancies. Many patients …
Controversial ectopic thyroid: a case report of thyroid tissue in the axilla and benign total thyroidectomy
HA Kuffner, BM McCook, R Swaminatha, EN Myers… - Thyroid, 2005 - liebertpub.com
A 43-year-old woman presented with a mass in her left axilla, which was surgically excised.
Histologically, the tissue was a reactive lymph node with adjacent thyroid follicular tissue. …
Histologically, the tissue was a reactive lymph node with adjacent thyroid follicular tissue. …
Physiologic uterine uptake of FDG during menstruation demonstrated with serial combined positron emission tomography and computed tomography
S Chander, CC Meltzer, BM McCOOK - Clinical nuclear medicine, 2002 - journals.lww.com
F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) has been used extensively
to stage, restage, and follow neoplastic disease. However, focal accumulation of FDG …
to stage, restage, and follow neoplastic disease. However, focal accumulation of FDG …
Role of 18FFDG PET/CT in the Treatment of Head and Neck Cancers: Principles, Technique, Normal Distribution, and Initial Staging
…, MB Fukui, BM McCook - American Journal of …, 2005 - Am Roentgen Ray Soc
Fig. 1.—Diagram illustrates principle of PET with 18FFDG: annihilation reaction. Positrons (β+)
released spontaneously from decaying fluorine-18 component of 18FFDG nucleus …
released spontaneously from decaying fluorine-18 component of 18FFDG nucleus …
Positron emission tomography/computed tomography: protocol issues and options
TM Blodgett, BM McCook, MP Federle - Seminars in nuclear medicine, 2006 - Elsevier
Combined positron emission tomography/computed tomography (PET/CT) became FDA-approved
for clinical use in late 2001. There are several design advantages of combined PET/…
for clinical use in late 2001. There are several design advantages of combined PET/…